Skip to content

Opioid-free anesthesia compared to standard anesthesia for bariatric surgery: clinical trial

Opioid-free anesthesia compared to opioid-based anesthesia for laparoscopic gastroplasty: a prospective, randomized, double-blind clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
REBEC
Registry ID
RBR-10tk7c76
Enrollment
Unknown
Registered
2022-08-01
Start date
2022-08-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity

Interventions

All patients will be randomly distributed, using specific software, into 2 groups: experimental (group E) represented by opioid-free anesthesia and control (group C) represented by opioid-based anesth
D02.241.081.751.756

Sponsors

Complexo Hospitalar Santa Genoveva
Lead Sponsor
Complexo Hospitalar Santa Genoveva
Collaborator

Eligibility

Age
No minimum to 65 Years

Inclusion criteria

Inclusion criteria: Patients included in the study protocol must meet the following prerequisites: age between 18 and 65 years; with a Body Mass Index (BMI) higher than 40 kg/m2 regardless of the presence of comorbidities or a BMI between 35 and 39.9 kg/ m2 in the presence of comorbidities; classified in the physical status ASA (American Society of Anaesthesiologists) of II or III; patients undergoing laparoscopic gastroplasty surgery under general anesthesia; expected hospital stay of up to 36 hours.

Exclusion criteria

Exclusion criteria: Patients who refuse to participate in the proposed study; patients who are younger than 18 and older than 65 years; who have a BMI (body mass index) lower than 35 kg/m2 or a BMI between 35 and 40 kg/m2 without comorbidities; patients who report adverse reactions to any drug included in the study; patients who have a history of alcohol or illicit substance abuse or chronic use of opioids for various reasons; patients who report liver or kidney failure; patients who have coexisting diseases that impair cognitive ability, such as poorly controlled psychiatric illnesses or neuropsychomotor developmental delay.

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is the assessment of the incidence of composite opioid-related adverse effects in the first hours after extubation and during hospitalization. The components of the composition will be nausea and vomiting, hypoxemia, defined as Sp02 below 90% with need for supplemental oxygen, and sedation, defined as a score greater or equal to 2 on the Wilson scale.

Secondary

MeasureTime frame
Bradycardia incidence (Heart rate less than 40 bpm);Arterial Hypotension (Mean arterial pressure less than 60 mmHg);Postoperative nausea and vomiting incidence (PONV);Postanestia care unit lenght of stay ;Hypoxemia incidence (SatO2 less than 90%);Pain burden;Pain intensity through verbal numeric rating scale (NRS);Rescue opioid consumption;Patient satisfaction through numeric verbal scale;Quality of Recovery using QoR-15 questionnaire

Countries

Brazil

Contacts

Public ContactSanta Genoveva Complexo Hospitalar

Complexo Hospitalar Santa Genoveva

ouvidoria@santagenoveva.net+55(34)3277-9000

Outcome results

None listed

Source: REBEC (via WHO ICTRP)